EFG Asset Management North America Corp. Acquires 40,611 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

EFG Asset Management North America Corp. boosted its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 120.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 74,300 shares of the biotechnology company's stock after acquiring an additional 40,611 shares during the period. Blueprint Medicines accounts for about 0.9% of EFG Asset Management North America Corp.'s investment portfolio, making the stock its 20th largest holding. EFG Asset Management North America Corp. owned about 0.12% of Blueprint Medicines worth $6,477,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Quarry LP bought a new position in shares of Blueprint Medicines in the 3rd quarter worth approximately $32,000. R Squared Ltd bought a new position in Blueprint Medicines during the fourth quarter valued at $51,000. Asset Management One Co. Ltd. purchased a new stake in shares of Blueprint Medicines in the fourth quarter worth approximately $88,000. Van ECK Associates Corp grew its holdings in shares of Blueprint Medicines by 48.2% in the fourth quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company's stock worth $97,000 after purchasing an additional 363 shares during the last quarter. Finally, Quantbot Technologies LP bought a new stake in Blueprint Medicines during the 3rd quarter valued at about $108,000.

Blueprint Medicines Stock Performance

Shares of NASDAQ BPMC traded down $1.01 during midday trading on Friday, reaching $88.72. 621,251 shares of the stock were exchanged, compared to its average volume of 729,152. The firm has a 50-day simple moving average of $98.13 and a two-hundred day simple moving average of $93.99. The firm has a market cap of $5.67 billion, a price-to-earnings ratio of -82.15 and a beta of 0.58. Blueprint Medicines Co. has a twelve month low of $80.68 and a twelve month high of $121.90. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15.

Remove Ads

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. As a group, analysts anticipate that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. JPMorgan Chase & Co. increased their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Needham & Company LLC reissued a "buy" rating and issued a $133.00 price objective on shares of Blueprint Medicines in a research note on Thursday, February 13th. Jefferies Financial Group assumed coverage on Blueprint Medicines in a report on Monday, March 17th. They issued a "buy" rating and a $135.00 price target on the stock. Wedbush reiterated an "outperform" rating and issued a $128.00 target price on shares of Blueprint Medicines in a research note on Friday, February 28th. Finally, Wolfe Research started coverage on shares of Blueprint Medicines in a research report on Tuesday, March 18th. They set an "outperform" rating for the company. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $124.95.

Insider Transactions at Blueprint Medicines

In other news, CEO Kate Haviland sold 1,446 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total value of $159,407.04. Following the sale, the chief executive officer now directly owns 149,378 shares in the company, valued at $16,467,430.72. This represents a 0.96 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey W. Albers sold 5,000 shares of Blueprint Medicines stock in a transaction on Monday, January 13th. The shares were sold at an average price of $102.28, for a total value of $511,400.00. Following the completion of the sale, the director now directly owns 157,557 shares of the company's stock, valued at approximately $16,114,929.96. This represents a 3.08 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 31,608 shares of company stock valued at $3,319,587. Corporate insiders own 4.21% of the company's stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.